chufangao/CTO huggingface dataset:
Clinical trial NCT04143594: Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV
Official title: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination With Other Antiretroviral Agents in People Living With HIV
Acronym: CALIBRATE
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 183.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-11-22
Primary completion date: 2021-10-05
Completion date: 2023-09-19
Baseline population: Safety Analysis Set included all participants who were randomized and received at least 1 dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment
IPD time frame: 18 months after study completion
IPD access criteria: A secured external environment with username, password, and RSA code.
Clinical trial NCT04028466: Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features
Official title: Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study
Sponsor: St. Luke's Medical Center, Philippines (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Budget for the study was withdrawn and discontinued
Enrollment: 82.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-26
Primary completion date: 2020-03-30
Completion date: 2020-03-30
Plan to share individual participant data: UNDECIDED
IPD sharing description: Approval from the Institutional review board should be secured before IPD will be made available
Clinical trial NCT04281004: Processed Amniotic Fluid (PAF) Drops After Photorefractive Keratectomy (PRK)
Official title: A Phase I/II Randomized, Double-Masked Placebo-Controlled Study For Determining The Safety Of Processed Amniotic Fluid (PAF) Drops After Photorefractive Keratectomy
Sponsor: University of Utah (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 61.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-10
Primary completion date: 2023-01-16
Completion date: 2023-01-16
Baseline population: The population includes all subjects who provide informed consent and who are randomized into the trial and who have analyzable primary outcome data for at least one PRK-treated eye.
Limitations and caveats: The limitations of this study include small sample size and limited duration for follow-up. A larger sample size may reveal whether pAF has a protective effect against haze formation, as haze after PRK is rare. Longer duration of follow-up can reveal whether it influences final visual acuity outcomes or late haze formation.
Plan to share individual participant data: NO
Clinical trial NCT04978818: Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)
Official title: Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children
Sponsor: Johns Hopkins Bloomberg School of Public Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 333.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-27
Primary completion date: 2023-10-26
Completion date: 2023-10-26
Plan to share individual participant data: NO
Clinical trial NCT04030247: Impact of Plant Sterol Supplement on LDL-C Lowering in Low-to-Moderate Risk South Asian Patients
Official title: Impact of Plant Sterol Supplement on LDL-C Lowering in Low-to-Moderate Risk South Asian Patients Participating in a Cardiovascular Disease Prevention Program
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-06
Primary completion date: 2021-03-31
Completion date: 2021-03-31
Baseline population: Participants who completed the protocol are included in the analysis.
Plan to share individual participant data: NO
Clinical trial NCT04421209: Analgesic Effects of Perioperative Propranolol Administration for Spine Surgery
Official title: Analgesic Effects of Perioperative Propranolol Administration for Spine Surgery
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No funding source
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-31
Primary completion date: 2021-06-30
Completion date: 2021-09-30
Plan to share individual participant data: NO
Clinical trial NCT01809002: Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair
Official title: A Multicenter, Prospective, Randomized, Subject and Evaluator Blinded Comparative Study of Nerve Cuffs and Avance® Nerve Graft Evaluating Recovery Outcomes for the Repair of Nerve Discontinuities
Acronym: RECON
Sponsor: Axogen Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 220.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-06-30
Primary completion date: 2021-08-30
Completion date: 2021-08-30
Limitations and caveats: It is important to refer to the population being analyzed and the analysis methodology, as certain analyses include a repeated measures mixed modeling approach to address missing or incomplete data, while other analyses were conducted with as reported data. This resulted in certain populations containing extrapolated data for missing or incomplete data points and others excluded those subjects from the analysis.
Plan to share individual participant data: NO
Clinical trial NCT06621342: Platelet Rich Plasma Uterine Infusion
Official title: Evaluating Cytokine Concentrations in the Endometrium Before and After Autologous Platelet Rich Plasma Uterine Infusion Preceding Frozen Embryo Transfer
Sponsor: University of Kansas Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Study deferred/stopped by initiator before any study recruitment was initiated.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-02-16
Primary completion date: 2023-02-16
Completion date: 2023-02-16
Plan to share individual participant data: NO
Clinical trial NCT03592277: Vitamin C & Thiamine to Treat Sepsis and Septic Shock
Official title: Vitamins B1 and C to Improve Outcomes in Patients With Severe Sepsis
Sponsor: Trinity Health Of New England (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 120.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-14
Primary completion date: 2021-02-22
Completion date: 2021-02-22
Plan to share individual participant data: NO
Clinical trial NCT03237182: The Individualized M(X) Drug-resistant TB Treatment Strategy Study
Official title: The Individualized M(X) Drug-resistant TB Treatment Strategy Study A Strategy to Improve Treatment Outcomes in Patients With Drug-resistant TB
Acronym: InDEX
Sponsor: Centre for the AIDS Programme of Research in South Africa (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: WHO 2022 guidelines for DR-TB treatment are set to change. These guidelines recommend the use of an all-oral short course BPAL regimen.Therefore ongoing implementation of the study is considered futile.
Enrollment: 205.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-14
Primary completion date: 2022-12-19
Completion date: 2022-12-19
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results of the objectives of the study, after deidentification
IPD time frame: Beginning 9 months and ending 36 months following article publication
IPD access criteria: Investigators wishing to access data from this study will need to contact the PI to request the data. Requests may be submitted up to 36 months following article publication. Investigators will need to complete a proposal for how the data will be used. The proposal will be reviewed by the CAPRISA Scientific Review Committee and the CAPRISA Executive Committee.
Clinical trial NCT04101682: Continuous Vs Single Shot Block After ACL
Official title: Continuous Vs Single Shot Adductor Canal Block After ACL Reconstruction - A Randomized Study
Sponsor: Northwell Health (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Not enough enrollment
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-25
Primary completion date: 2022-05-17
Completion date: 2022-05-17
Plan to share individual participant data: NO
Clinical trial NCT02797067: Rectal Indomethacin to Prevent Post ESWL-pancreatitis
Official title: Rectally Administered Indomethacin to Prevent Post-ESWL-pancreatitis (RIPEP)
Acronym: RIPEP
Sponsor: Changhai Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 1370.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-05-31
Primary completion date: 2019-07-31
Completion date: 2021-08-31
Plan to share individual participant data: NO
Clinical trial NCT05978063: Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica
Official title: A 2-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate-to-Severe Pruritus in Adult Subjects With Notalgia Paresthetica
Sponsor: Cara Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: In Part A of CR845-310601, oral difelikefalin did not demonstrate a meaningful clinical benefit at any dose compared to placebo. The drug was generally well tolerated with a safety profile similar to prior trials.
Enrollment: 214.0 (ACTUAL)
Number of arms: 4.0
Start date: 2023-08-01
Primary completion date: 2024-04-22
Completion date: 2024-05-07
Plan to share individual participant data: NO
Clinical trial NCT04184323: SIRT-1 Antagonism for Endometrial Receptivity
Official title: SIRT1-1 Antagonist Therapy Before Embryo Transfer to Improve Endometrial Receptivity and Life Pregnancy Rates
Acronym: SAFER
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-31
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Plan to share individual participant data: YES
IPD sharing description: The demographic data, group assignment, and outcome data for each subject will be shared with other researchers including embryo grade, stage, pregnancy results (pregnant, not pregnant, miscarriage, ongoing pregnancy, Live birth)
IPD time frame: After completion of the study that includes live birth data
Clinical trial NCT04631705: SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation
Official title: A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals
Sponsor: University of Cologne (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Change in viral variant epidemiology
Enrollment: 45.0 (ACTUAL)
Number of arms: 7.0
Start date: 2020-12-14
Primary completion date: 2021-09-23
Completion date: 2021-09-23
Limitations and caveats: - Small sample size, further reduced by early termination
Plan to share individual participant data: NO
Clinical trial NCT03688568: Study of Imatinib in Children With Neurofibromatosis and Airway Tumors
Official title: Phase 2 Study of Imatinib in Children With Neurofibromatosis and Airway Tumors
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Enrollment not feasible
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-09-01
Primary completion date: 2020-09-01
Completion date: 2021-09-01
Plan to share individual participant data: NO
Clinical trial NCT03794258: Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection
Official title: A Phase 2a, Open-label, Randomized Study of the Safety and Preliminary Efficacy of Triple or Quadruple Combination DAAs With Ultra-short Duration Therapy in Subjects With HCV Genotype 1b Infection (YANGTZE Study)
Sponsor: Humanity & Health Medical Group Limited (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Can not recruit the patients due to the pandemic of COVID-19
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-01
Primary completion date: 2020-04-15
Completion date: 2020-04-30
Clinical trial NCT05212662: Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19
Official title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Study to Assess the Safety, Tolerability, Pharmacodynamics (PD) and Efficacy of TTI-0102 for the Treatment of Patients With Mild to Moderate COVID-19
Sponsor: Thiogenesis Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor is not pursuing the COVID-19 indication at this time.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-09-27
Primary completion date: 2024-09-27
Completion date: 2024-09-27
Plan to share individual participant data: NO
Clinical trial NCT03072238: Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Official title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
Acronym: IPATential150
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1101.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-30
Primary completion date: 2020-03-16
Completion date: 2024-04-24
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT03353350: Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
Official title: A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
Acronym: AMPLITUDE-M
Sponsor: Hanmi Pharmaceutical Company Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 406.0 (ACTUAL)
Number of arms: 4.0
Start date: 2017-12-05
Primary completion date: 2020-01-29
Completion date: 2020-09-07
Plan to share individual participant data: NO
Clinical trial NCT01438684: The Impact of RPh201 on Chronic Vegetative State (CVS): fMRI Study
Official title: Phase 1 Study of RPh201 in Patients With Chronic Vegetative or Minimal Conscious State
Acronym: RPh-in-CVS
Sponsor: Hadassah Medical Organization (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: due to lack of supply of medication and technical problems with the MRI
Enrollment: 10.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2012-09-30
Primary completion date: 2019-01-31
Completion date: 2020-10-31
Clinical trial NCT04397458: Rescue Quadratus Lumborum Blocks for Post-cesarean Pain
Official title: Rescue Quadratus Lumborum Blocks for Post-cesarean Pain
Sponsor: The University of Texas Health Science Center, Houston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: COVID-19 pandemic and competing study that took precedence
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-01
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Plan to share individual participant data: NO
Clinical trial NCT03740997: Study to Determine Safety and Dosage of OPTISON in Pediatric Participants
Official title: A Phase 4, Open-Label, Non-Randomized, Multicenter Study to Evaluate Safety and Efficacy of Intravenous Administration of OPTISON™ for Contrast- Enhanced Echocardiography in Pediatric Patients
Sponsor: GE Healthcare (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 39.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-01
Primary completion date: 2023-03-30
Completion date: 2023-03-30
Baseline population: The Safety population consisted of all enrolled participants who received \>=1 dose of OPTISON in the study.
Clinical trial NCT05047601: A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
Official title: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332/RITONAVIR IN PREVENTING SYMPTOMATIC SARS-COV-2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID-19
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 2954.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-09-09
Primary completion date: 2022-04-12
Completion date: 2022-04-12
Baseline population: FAS (Full Analysis Set) included all participants randomly assigned to study intervention regardless of whether or not study intervention was administered.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04371653: A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease
Official title: A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Nonalcoholic Fatty Liver Disease (NAFLD)
Sponsor: The University of Texas Health Science Center, Houston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: lack of funds
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-12-01
Primary completion date: 2024-12-01
Completion date: 2024-12-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03995901: A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation
Official title: A Randomized, Controlled, Multi-center, Safety and Efficacy Study of FCR001 Cell-based Therapy Relative to a Tacrolimus and Mycophenolate-based Regimen in de Novo Living Donor Renal Transplant Recipients, and Safety in FCR001 Donors
Acronym: FREEDOM-1
Sponsor: Talaris Therapeutics Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Talaris decided to discontinue living donor kidney transplant development program
Enrollment: 15.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-25
Primary completion date: 2023-02-16
Completion date: 2023-02-16
Plan to share individual participant data: NO
Clinical trial NCT03838692: Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Official title: A Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer (MTC)
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Closed by sponsor
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-26
Primary completion date: 2021-06-14
Completion date: 2021-06-14
Plan to share individual participant data: NO
Clinical trial NCT04932915: Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19
Official title: A Randomized Placebo-controlled Phase 2 Study to Assess the Safety and Efficacy of UNI91103 Intranasal Administration in Adults With Asymptomatic or Mildly Symptomatic COVID-19
Acronym: PREVENT
Sponsor: UNION therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Failure of recruiting patients
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-03
Primary completion date: 2022-01-10
Completion date: 2022-01-10
Plan to share individual participant data: NO
Clinical trial NCT03363659: Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme
Official title: A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate When Added to Standard Temozolomide Treatment in Patients With Newly Diagnosed Resected Unmethylated Glioblastoma Multiforme
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Investigator decision
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-28
Primary completion date: 2022-01-13
Completion date: 2022-01-13
Baseline population: 15 subjects consented, 1 subject was a screen fail and 1 subject withdrew before any planned intervention.
Plan to share individual participant data: NO
Clinical trial NCT04994431: Post-Operative Urinary Retention (POUR) in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin
Official title: Post-Operative Urinary Retention (POUR) in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin
Acronym: POUR
Sponsor: University of Massachusetts, Worcester (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: inability to recruit
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-01
Primary completion date: 2023-10-04
Completion date: 2023-10-04
Plan to share individual participant data: NO
IPD sharing description: No plan to share data